Table 1.
Demographic and neurophysiological characteristics of the healthy controls and the patients
| Controls (n = 20) | Patients (n = 19) | |||||
|---|---|---|---|---|---|---|
| Placebo (n = 17) | 25 μg (n = 17) | 50 μg (n = 19) | 75 μg (n = 19) | 150 μg (n = 15) | ||
| Mean age (SD) | 33.45 (6.41) | 37.78 (6.21)* | ||||
| Antipsychotic medication, typical/atyical/both | 2/14/3 | |||||
| Mean PANSS scores (SD) | ||||||
| Positive | 12.82 (5.26) | 14.47 (7.09) | 12.67 (4.52) | 13.78 (6.70) | 11.50 (2.28) | |
| Negative | 13.82 (5.08) | 16.06 (4.42) | 15.39 (5.95) | 15.38 (5.09) | 14.13 (4.76) | |
| General | 24.24 (6.58) | 25.82 (7.00) | 25.11 (7.18) | 25.67 (6.96) | 23.44 (4.44) | |
| Total | 50.76 (14.58) | 56.88 (15.70) | 53.11 (14.57) | 54.83 (16.48) | 48.94 (9.07) | |
| Mean MMN amplitudes (SD) | ||||||
| Freq deviant | −2.32 (0.82) | −2.25 (1.00) | −2.86 (1.27) | −2.65 (1.35) | −2.77 (1.55) | −3.16 (1.17) |
| Duration deviant | −4.03 (1.29) | −2.82 (1.33)* | −2.67 (1.64)* | −3.01 (1.62)* | −2.68 (1.27)* | −3.22 (1.64) |
| FreqDur deviant | −3.61 (1.04) | −2.84 (1.08)* | −3.46 (1.93) | −3.22 (1.56) | −3.06 (1.27) | −3.36 (1.24) |
| Mean P3a amplitudes (SD) | ||||||
| Freq deviant | 2.81 (1.31) | 2.68 (1.02) | 2.36 (1.16) | 2.57 (0.97) | 2.40 (1.11) | 2.90 (1.27) |
| Duration deviant | 3.58 (1.55) | 2.56 (1.22)* | 1.97 (1.15)* | 2.84 (1.33) | 2.40 (1.07)* | 2.76 (1.52) |
| FreqDur deviant | 4.61 (1.40) | 3.16 (1.44)** | 2.70 (1.23)** | 3.40 (1.32)** | 2.99 (1.14)** | 3.16 (1.44)** |
PANSS Positive and Negative Symptom Scale, MMN mismatch negativity, Freq frequency, FreqDur frequency–duration
*Significant group difference at p < 0.05
**Significant group difference at p < 0.001